Cohort study identifies risk factors for taxane-induced peripheral neuropathy in early-stage cancer, suggesting a model for better treatment decisions.
In this cohort study of participants with early-stage cancer receiving a taxane regimen, a set of baseline risk factors stratified TIPN risk. A risk prediction model may guide treatment decision-making, symptom monitoring, and enrollment in interventional trials for TIPN prevention and treatment.
No takes yet. Share an insight, caveat, or question.
Trivedi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: